Company: SHPH
Filing Date: 2025-02-27
Form Type: 424B3
Source: 0001493152-25-008476
Chunk: 1

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-27
Form: 424B3
Chunk 1
---
 “Shares”).

You should read this prospectus supplement in conjunction with the Prospectus, including any amendments or supplements to it. This prospectus supplement is qualified by reference to the Prospectus, except to the extent that the information provided by this prospectus supplement supersedes information contained in the Prospectus. This prospectus supplement is not complete without and may not be delivered or used except in conjunction with, the Prospectus, including any amendments or supplements to it. You should keep this prospectus supplement with your Prospectus for future reference.

Our common stock is listed on the Nasdaq Capital Market under the symbol “SHPH.” On February 26, 2025, the closing price of our common stock was $0.60.

We are an “emerging growth company” under federal securities laws and are subject to reduced public company reporting requirements. Investing in our securities involves a high degree of risk. See the section entitled “Risk Factors” beginning on page 12 of the Prospectus, and under similar headings in any amendments or supplements to the Prospectus, and beginning on page 21 of our Annual Report on Form 10-K contained herein.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

<div align='center'>The date of this prospectus supplement is February 27, 2025.</div>

<div align='center'>TABLE OF CONTENTS</div>

| ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2024 |
|:----------------------------------------------------------------|
| CONSENT OF FORVIS MAZARS, LLP                                   |

<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K</div>

(Mark One)

| ☒ | ANNUAL                                 
 REPORT PURSUANT TO SECTION 13 OR 15(d) 
 OF THE SECURITIES EXCHANGE ACT OF 1934 |

<div align='center'>For the fiscal year ended December 31, 2024

or</div>

| ☐ | TRANSITION                             
 REPORT PURSUANT TO SECTION 13 OR 15(d) 
 OF THE SECURITIES EXCHANGE ACT OF 1934 |

<div align='center'>For the transition period from ______________ to ______________

Commission file number: 001-41488

Shuttle Pharmaceuticals Holdings,